The Trump administration is dramatically restructuring how America distributes essential medical supplies to combat HIV and malaria in developing nations, according to multiple sources and internal government communications, potentially creating dangerous disruptions in life-saving healthcare services.
Since 2016, the United States has operated medical supply distribution through the Global Health Supply Chain Program managed by private contractor Chemonics. This initiative has shipped over $5 billion worth of HIV and malaria treatments to 90 nations, primarily across sub-Saharan Africa and Asia.
The program faced initial disruption when President Trump implemented a freeze on international aid during his first day in office this past January, leaving millions of dollars in medical supplies stuck at ports and storage facilities. These included critical HIV medications and insecticide-treated mosquito nets. Operations partially resumed after the administration granted exemptions for life-saving products.
However, the program’s long-term future remains uncertain as the current administration reshapes foreign assistance, dissolving the U.S. Agency for International Development (USAID), reducing funding, and transitioning from contractor management to direct agreements with recipient nations.
According to five sources, the accelerated timeline for these changes may result in medication shortages or service interruptions in certain countries, with potentially severe consequences.
An internal State Department message sent Tuesday to U.S. personnel in 17 African nations and Haiti directed them to discontinue the supply program operations by May 30. The communication indicated that the Chemonics contract would terminate September 30, aligning with all USAID agreements, though the official contract expiration is November.
The internal email, which Reuters obtained and two sources confirmed, warned of “immediate risks to service continuity if (the) transition is rushed or incomplete.”
Rather than providing a detailed transition strategy, the message instructed each U.S. country office to develop their own handover plans and report any risks or requests for additional time to Washington.
A State Department representative stated they had “not provided any technical direction to Chemonics to cease operations by May 30 or any other date.” Chemonics declined to provide comment.
Six sources indicated the U.S. government is in discussions with the Global Fund to Fight AIDS, Tuberculosis and Malaria regarding use of their supply platform for future procurement and distribution of global health donations.
The Geneva-based Global Fund currently oversees approximately $2 billion annually in health product purchases for these three infectious diseases, working alongside partner organizations in recipient countries. The organization also operates an online procurement system utilized by partners.
Two sources revealed that previous discussions between the organization and U.S. officials had centered on a November 2027 transition timeline. They described the new accelerated schedule as impractical, noting that ordering medical supplies for remote locations typically requires up to one year, not the weeks currently being considered.
The Global Fund declined to comment. The State Department did not address specific questions about discussions with the Fund, but stated it would utilize available pooling mechanisms to purchase supplies at reduced costs from private manufacturers.
Last year, the Trump administration announced its global health initiatives would emphasize funding front-line medical supplies, healthcare workers and technicians, while working directly with individual countries.
The America First Global Health Strategy, released in September, identified contractors as contributing to “significant inefficiency and waste” that the administration seeks to eliminate from the system.
However, the rapid pace of changes to U.S. aid delivery has already created worldwide problems, including shortages of childhood malaria medications and gaps in HIV prevention services.
The State Department spokesperson characterized the current system as “a bloated piece of an obsolete development model” that “does not put the American taxpayers first and instead helps to line the pockets of large U.S.-based development firms.”
They noted the U.S. government has established 28 bilateral health agreements with recipient governments and plans to primarily utilize private logistics companies for supply distribution.
In recent months, Washington has committed to providing direct funding to governments including Kenya, Rwanda and Uganda, accompanied by promises of increased national spending.
However, specifics are still being finalized. The Kenya agreement faces legal challenges from Kenyan activists concerning data privacy issues, while negotiations with Zambia’s government have experienced delays.
